Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
Minoru NakazonoNobuyoshi KosakaKosuke IwataniYu ImaiKojiro TashiroMariko HondaYusuke KoikeTatsuya ShimomuraShun SatoHiroyuki TakahashiKenta MikiManabu AokiTakahiro KimuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
Our long-term data suggest that in the presence of a PSA level ≤ 0.2 ng/mL at 8 years later, PSA monitoring may be safely discontinued due to the extremely low risk of subsequent oncological events. The data presented in this study will assist clinicians in determining the optimal management strategy for patients with PCa following HDR-BT and EBRT combined with long-term ADT.